Skip to content
lifestyle.ebusinessplanet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NEUROCRINE BIOSCIENCES, INC.
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
August 12, 2026
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-‘1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
August 7, 2026
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
July 30, 2026
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
May 18, 2026
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
May 18, 2026
←
Previous Page
1
2